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ABSTRACT
Introduction. Electrocardiography (ECG) is a widely used non-invasive diagnostic method for assess-
ment of patients with cardiovascular diseases. Numerous different electrocardiographic criteria exist for 
detection of left ventricular hypertrophy (LVH). LVH is an important risk factor in patients with coronary 
artery disease (CAD) or diabetes mellitus and its presence is associated with increased cardiovascular 
morbidity and mortality. The aim of this study was to evaluate the prevalence of the most frequently used 
electrocardiographic left ventricular hypertrophy (ECG-LVH) criteria among patients with CAD and diabetes.
Methods. A cross-sectional, multicenter study was conducted in outpatient clinics across Poland. Family 
physicians performed physical examinations and collected relevant information about: onset of CAD and 
diabetes, presence and onset of hypertension, dyslipidemia, heart failure, diabetic complications, history 
of acute coronary syndrome and pharmacotherapy. In order to detect LVH, we used seven ECG criteria: 
1) the Sokolow-Lyon voltage, 2) the Gubner voltage, 3) the criterion of the R wave amplitude on the leads 
V5–V6 and 4) aVL, 5) the gender specific Cornell voltage and 6) product, and 7) the Romhilt-Estes point 
score. Centralized manual assessment of the obtained ECG tracings were performed.
Results. We enrolled 1001 patients (48.5% women, 51.5% men, mean age 65 ± 11 years) into the study. At 
least one ECG-LVH criterion was met in 20.0% (n = 200) of the study participants. The ECG-LVH diagnosis 
was the most common when using the Romhilt-Estes point score (n = 138; 13.8%). The corresponding 
prevalence rates for the Cornell voltage, the Cornell product, the R wave amplitude on the lead aVL, the 
Sokolow-Lyon voltage, the Gubner voltage and the R wave amplitude on the leads V5-V6 criteria were 
5.5% (n = 55), 5.2% (n = 52), 3.2% (n = 32), 2.2% (n = 22), 1.9% (n = 19) and 1.3% (n = 13) respectively. 
Subsequently, the prevalence of the three most frequently used in clinical practice electrocardiographic 
criteria for LVH (the Sokolow-Lyon voltage, the Cornell voltage and the Romhilt-Estes point score) was 
analyzed. At least one of them was fulfilled in 185 ECGs. All three criteria at the same time were met only 
in 5 ECGs (2.7% of 185). Two and only one out of three criteria were fulfilled in 20 (10.8%) and 160 (86.5%) 
ECGs respectively.
Conclusions. The co-occurrence of all assessed ECG-LVH criteria, including the three most frequently 
applied in clinical practice, is very low in diabetic CAD patients. The Romhilt-Estes point score identifies the 
highest number of ECG-LVH cases in this setting. However, it seems reasonable to use routinely several 
ECG criteria for detection of LVH. Further studies are needed to compare diagnostic values of ECG-LVH 
criteria with imaging methods and to assess prognostic values of various ECG-LVH criteria.
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Introduction
Electrocardiography (ECG) is over 100 years old, 
but due to its simplicity, non-invasiveness, significant 
prognostic value and wide availability still remains rou-
tinely used for assessment of patients with suspected 
and diagnosed cardiovascular diseases. Numerous 
different electrocardiographic criteria exist for detection 
of left ventricular hypertrophy (LVH), but only several 
methods are used in clinical practice. Electrocardio-
graphic evidence of LVH is a powerful and independent 
predictor of increased cardiovascular morbidity and 
mortality [1–6]. 
LVH often coexists with coronary artery disease 
(CAD) and diabetes mellitus. Additionally, the latter is 
considered a major cardiovascular risk factor associat-
ed with accelerated atherosclerosis and increased risk 
of micro- and macroangiopathies in subjects with and 
without diagnosed CAD [7–11]. As LVH progresses, 
myocardial oxygen demand increases, which may 
cause exacerbation of CAD and potentially lead to 
acute cardiovascular events. Interestingly, several 
studies have suggested that diabetes may be asso-
ciated with left ventricular structural and functional 
abnormalities [12–14]. Diabetic patients exhibit higher 
left ventricle wall thickness, mass and more concentric 
geometry than those without diabetes. Importantly, 
cardiovascular morbidity and mortality increase pro-
gressively with left ventricular muscle mass [15–20].
The aim of this study was to evaluate the prevalence 
of the most frequently used electrocardiographic left 
ventricular hypertrophy (ECG-LVH) criteria among 
patients with CAD and diabetes mellitus. 
Methods
Study design and conduct
A cross-sectional, multicenter study was conducted 
among patients with CAD and diabetes by family physi-
cians in primary care centers in Poland in 2009. Inclu-
sion criteria were: 1) previous angiographically proven 
clinical diagnosis of CAD, 2) previous diagnosis of type 2 
diabetes mellitus according to the American Diabetes 
Association criteria, and 3) provision of informed con-
sent for the study participation, while exclusion criteria 
included: 1) the presence of ventricular pacing, 2) the 
presence of left or right bundle branch block, 3) the 
presence of left anterior or posterior hemiblock, and 
4) inability of adequate ECG assessment and interpre-
tation caused by technical reasons. For each patient, 
a thorough history was taken and detailed physical 
examination was performed. Blood pressure was 
measured by a physician with a mercury sphygmo-
manometer or an automated device in the outpatient 
clinic in a quiet and relaxed environment, with the 
subject seated for at least 10 minutes. The average of 
two measurements was used for the analysis. Collected 
information from the medical history included: history of 
hypertension, dyslipidemia, gout, heart failure, diabetic 
complications (diabetic foot, retinopathy, nephropathy 
and neuropathy), previous stroke and acute coronary 
syndrome as well as duration of hypertension, diabe-
tes and CAD. Hypertension was defined as systolic 
blood pressure ≥ 140 mm Hg and/or diastolic blood 
pressure ≥ 90 mm Hg or treatment with anti-hyperten-
sive drugs. Measured laboratory parameters included: 
fasting plasma glucose, glycated hemoglobin (HbA1c), 
total cholesterol, high-density lipoprotein (HDL) cho-
lesterol, low-density lipoprotein (LDL) cholesterol and 
triglycerides. The aforementioned results were taken 
from patient documentation when measured within 
12 months. Detailed information on participants’ phar-
macological treatment during the last 6 months was 
recorded, including the use of metformin, sulfonylurea 
derivatives, insulin, acetylsalicylic acid, clopidogrel, 
statins, fibrates, angiotensin-converting enzyme inhib-
itors, angiotensin II receptor blockers, beta-adrenolyt-
ics, diuretics and calcium channel antagonists.
The study protocol was approved by the Local 
Ethics Committee in accordance with the Declaration 
of Helsinki.
Electrocardiography
Standard supine 12-lead electrocardiograms were 
registered at a 25 mm/s speed and 10 mm/mV gain. 
ECGs were read according to the AHA/ACCF/HRS 
Recommendations for the Standardization and Inter-
pretation of the Electrocardiogram [21]. Centralized 
measurements were performed in all ECGs manually, 
questionable cases were resolved by consensus of 
experienced cardiologists. In order to detect LVH, we 
used seven methods, including various voltage criteria 
and point score system. Electrocardiographic criteria 
for the LVH diagnosis were as follows: 1) the Sokolow- 
-Lyon voltage — sum of the S wave in lead V1 and 
the largest R wave in the lead V5 or V6 ≥ 3.5 mV [22], 
2) the criterion of the R wave amplitude in the lead V5 or 
V6 ≥ 2.6 mV [22], 3) the criterion of the R wave ampli-
tude in the lead aVL ≥ 1.1 mV [23], 4) the Gubner volt-
age — sum of the R wave in the lead I and the S wave in 
the lead III ≥ 2.5 mV [24], 5) the gender specific Cornell 
voltage — sum of the R wave in the lead aVL and the 
S wave in the lead V3 ≥ 2.0 mV in women and ≥ 2.8 mV in 
men [25], 6) the gender specific Cornell product — sum 
of the R wave in the lead aVL and the S wave in the 
lead V3 (for women, added 8 mm), all multiplied by the 
mean QRS interval, result ≥ 2436 mm was considered 
positive for LVH [26], and 7) the Romhilt and Estes 
point score [27]. The latter comprises amplitudes of 
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the R or S waves > 20 mm in the limb leads (1 point) 
or > 30 mm in precordial leads (1 point), ST-T segment 
strain pattern in V5 or V6 (3 points, but when using dig-
italis — it is only 1 point), the P wave amplitude > 1mm 
and duration > 40 ms in the lead V1 (3 points), QRS 
electrical axis > –30 degrees (2 points); QRS dura-
tion > 90 ms in the lead V6 (1 point) and initial time of 
the intrinsicoid deflection of the QRS > 50 ms in V5 or 
V6 (1 point). In the Romhilt-Estes point score, LVH is 
diagnosed when the score is ≥ 5 points.
We prespecified an additional analysis including 
the three most frequently applied in clinical practice 
ECG criteria for detection of LVH — the Sokolow-Lyon 
voltage, the Cornell voltage and the Romhilt-Estes 
point score.
Statistical analysis
Results are shown as mean ± standard deviation 
(SD) for continuous variables and as number and per-
cent for categorical variables. Continuous data were 
checked for normal distribution by means of Shapiro- 
-Wilk W test. Differences in clinical characteristics 
between patients with and without ECG-LVH were 
assessed using the Chi-square test for categorical vari-
ables and the Student’s t-test for normally distributed 
continuous variables. The non-parametric Mann-Whit-
ney U test and the ANOVA Kruskal-Wallis test were 
applied for comparisons of continuous variables whose 
distribution deviated from normality. Spearman’s rank 
correlation coefficient was used to determine strength 
of relationship between tested variables. A two-sided 
difference was considered significant at p < 0.05. The 
statistical analysis was carried out using the Statistica 
9.1 package (StatSoft, Tulsa, OK, USA).
Results
Out of 1116 potentially eligible patients, 1001 sub-
jects (485 women and 516 men) were enrolled into the 
study. We excluded 115 participants due to: paced 
rhythm in the assessed ECG (n = 18 cases), the pres-
ence of left or right bundle branch block (n = 76) or 
inability of adequate ECG assessment and interpreta-
tion caused by technical reasons (n = 21). The clinical 
characteristic of the study population is reported in 
Table 1.
There were 200 patients (20.0%) who met at least 
one ECG criteria for LVH. In details, we found electrocar-
diographic evidence of LVH fulfilling at least 1 criterion 
in 99 women (20.4%) and in 101 men (19.6%). The 
prevalence of LVH varied widely due to the criteria used. 
There was no patient fulfilling all seven LVH criteria. 
The prevalence of LVH was the highest when using the 
Romhilt-Estes point score (13.8%) and the lowest when 
using the criterion of the R wave amplitude in the lead 
V5 or V6 (1.3%) (Tab. 2).
At least one of the three most frequently used crite-
ria, the Sokolow-Lyon voltage, the Cornell voltage and 
the Romhilt-Estes point score, was met in 185 patients 
(18.5% of all 1001 patients), while all three criteria at 
the same time were fulfilled only in 5 patients (2.7% of 
185 patients with at least one of the three above listed 
criteria). Two out of the three above mentioned criteria 
at the same time were met in 20 patients (10.8%): the 
Sokolow-Lyon voltage and the Cornell voltage in 3 pa-
tients (1.6%), the Sokolow-Lyon voltage and the Rom-
hilt-Estes point score in 6 patients (3.2%) and the Cornell 
voltage and the Romhilt-Estes point score in 11 patients 
(6.0%). Only one criterion was met in the large majority 
of patients — 160 (86.5%): the Sokolow-Lyon voltage 
in 8 patients (4.3%), the Cornell voltage in 36 patients 
(19.5%) and the Romhilt-Estes point score in 116 pa-
tients (62.7%) (Fig. 1).
Differences in clinical characteristics among 
patients meeting commonly used ECG criteria for 
LVH (the Sokolow-Lyon voltage, the Cornell voltage 
and the Romhilt-Estes point score) are presented in 
Table 3. 
We found a trend showing positive correlation be-
tween duration of hypertension and magnitude of the 
Sokolow-Lyon voltage criterion (r = 0.38, p = 0.095) 
but no correlation with either systolic or diastolic blood 
pressure. There were no correlations between either 
blood pressure levels or duration of hypertension and 
magnitude of the Cornell voltage criterion. 
Discussion
Large amount of research evidence indicates that 
sensitivity of traditional electrocardiographic criteria for 
LVH is relatively poor when compared with the refer-
ence standard for LVH assessment – echocardiogra - 
phy [28–34]. However, Verdecchia et al. and Schillaci 
et al. suggest that using the combination of three highly 
specific criteria: the Romhilt-Estes point score, left 
ventricular strain and Cornell criteria in a cumulative 
score can produce a rise in sensitivity without excessive 
deterioration of specificity [35, 36]. Importantly, even 
single electrocardiographic criteria for LVH are highly 
specific, with specificity exceeding 90% [37].
In a population of patients with CAD and concom-
itant diabetes, we found that the prevalence of LVH 
detected by ECG was 20% and ranged widely from 1% 
to 14%, depending on the criterion used. The LIFE study 
demonstrated that diabetes is associated with an in-
creased prevalence and severity of ECG-LVH assessed 
according to the Cornell criteria [38]. In contrast, in high-
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Figure 1. Coexistence of the three most frequently used 
ECG-LVH criteria; ECG-LVH — electrocardiographic left 
ventricular hypertrophy. Percentages are calculated out of 
all patients who fulfilled at least one of the three assessed 
ECG-LVH criteria (n = 185)
-risk patients in the HOPE study, there was no difference 
in the prevalence of diabetes between patients with and 
without ECG-LVH determined using the Sokolow-Lyon 
criterion [39]. In our population of diabetic patients with 
CAD, the prevalence of the Cornell voltage criterion was 
about 6%, while the prevalence of the Sokolow-Lyon 
voltage criterion was only 2%.
Bruno et al. investigated ECGs of 965 patients with 
type 2 diabetes mellitus and assessed the prevalence 
of ECG-LVH and its relationship with clinical and meta - 
bolic variables [40]. Patients with ECG-LVH were 
older than those without it, but there were no further 
differences in terms of body mass index, duration of 
diabetes, diabetes treatment, systolic and diastolic 
blood pressure, presence of CAD or hypertension. 
Interestingly, the comparison of patients with and 
without ECG-LVH in our study revealed that the former 
subjects were more often treated with beta-adrenolyt-
ics and statins. 
According to our observations, it seems insuffi-
cient to use only one ECG criterion for detection of 
LVH in patients with CAD and DM, because each 
criterion identifies a different group of patients. In our 
study, 86.5% of subjects met only one out of the three 
most frequently used electrocardiographic criteria. It 
suggests the criteria are complementary and should 
be used in combination in order to detect ECG-LVH. 
González-Juanatey et al. indicated that the Cornell and 
Sokolow-Lyon diagnostic criteria enable us to identify 
hypertensive patients with LVH with different epidemi-
ologic and cardiovascular risk profiles [41]. In men, 
LVH was preferably diagnosed using the Sokolow-Lyon 
criterion, whereas women more frequently fulfilled the 
Cornell criterion. In our study, the Sokolow-Lyon crite-
rion was fulfilled in 2.7% of men and in 1.6% of women, 
while the Cornell criterion was met in 3.5% of men and 
in 7.6% of women.
The severity of ECG-LVH may be assessed by 
determining the magnitude of the voltage criteria. 
González-Juanatey et al. found positive correlations 
Table 2. Prevalence of left ventricular hypertrophy based on seven assessed electrocardiographic criteria
Criterion All analyzed patients
(n = 1001)
n (%)
Men
(n = 516)
n (%)
Women
(n = 485)
n (%)
The R wave amplitude on the lead V5 or V6 criterion 13 (1.3) 8 (1.6) 5 (1.0)
The Gubner voltage criterion 19 (1.9) 10 (1.9) 9 (1.9)
The Sokolow-Lyon voltage criterion 22 (2.2) 14 (2.7) 8 (1.6)
The R wave amplitude on the lead aVL criterion 32 (3.2) 17 (3.3) 15 (3.1)
The Cornell product criterion 52 (5.2) 24 (4.7) 28 (5.8)
The Cornell voltage criterion 55 (5.5) 18 (3.5) 37 (7.6)
The Romhilt-Estes point score 138 (13.8) 78 (15.1) 60 (12.4)
between systolic and diastolic blood pressure levels 
and severity of both the Sokolow-Lyon and the Cornell 
voltage criteria [41]. We also analyzed the severity of 
ECG-LVH reflected by the magnitude of the Sokolow- 
-Lyon and the Cornell voltage criteria. In our study, there 
was a trend showing that the severity of LVH due to the 
Sokolow-Lyon criterion positively correlated with the 
duration of hypertension. However, we failed to find any 
correlations between the severity of the Cornell voltage 
and blood pressure levels or duration of hypertension. 
Importantly, a large majority of our study participants 
were treated with antihypertensive drugs.
There are some limitations of the study that deserve 
attention. First of all, ECGs were recorded in our study 
using analog, but not digital, systems and therefore 
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Table 3. Clinical characteristics of patients meeting the three most frequently used electrocardiographic criteria of left 
ventricular hypertrophy
Clinical feature The Sokolow-Lyon 
criterion
(n = 8)
The Cornell
voltage criterion
(n = 36)
The Romhilt-Estes 
point score
(n = 116)
p
Age (years) 68.1 ± 6.3 65.6 ± 9.3 65.0 ± 9.6 0.54
Height [cm] 169.5 ± 8.1 166.4 ± 6.8 167.7 ± 8.8 0.53
Weight [kg] 81.4 ± 15.2 86.7 ± 18.3 85.1 ± 12.1 0.62
BMI [kg/m2] 28.3 ± 4.7 31.3 ± 6.8 30.3 ± 4.1 0.39
Waist circumference [cm] 96.1 ± 11.4 100.1 ± 16.0 98.2 ± 12.6 0.61
Hips circumference [cm] 106.0 ± 10.7 110.0 ± 14.8 106.3 ± 12.9 0.53
Heart rate [beats/min] 65.5 ± 13.9 75.5 ± 13.1 74.4 ± 14.5 0.08
Systolic blood pressure [mm Hg] 146.6 ± 15.1 142.0 ± 15.1 138.2 ± 14.2 0.11
Diastolic blood pressure [mm Hg] 86.1 ± 10.6 83.3 ± 8.6 82.6 ± 11.0 0.70
Duration of CAD (years) 2.6 ± 2.8 7.8 ± 5.4 6.2 ± 6.2 < 0.05
Duration of diabetes (years) 8.4 ± 5.8 13.7 ± 9.2 8.5 ± 6.6 < 0.01
Duration of hypertension (years) 14.9 ± 9.1 14.9 ± 10.1 10.8 ± 7.0 0.06
Duration of dyslipidemia (years) 9.6 ± 5.6 13.4 ± 7.7 9.3 ± 6.7 0.09
Duration of microangiopathy (years) 1.5 ± 1.0 6.6 ± 4.3 7.0 ± 6.0 < 0.05
Duration of heart failure (years) 4.8 ± 4.3 7.8 ± 6.1 5.3 ± 4.1 0.49
Duration of ACEI treatment (years) 6.8 ± 2.6 9.2 ± 5.3 7.8 ± 4.4 0.33
Fasting plasma glucose [mg/dL] 114.2 ± 16.0 135.6 ± 44.9 127.3 ± 31.2 0.62
HbA1c (%) 6.0 ± 0.0 7.1 ± 1.2 7.1 ± 1.1 0.51
Total cholesterol [mg/dL] 206.3 ± 24.6 210.2 ± 61.3 213.6 ± 100.0 0.83
HDL cholesterol [mg/dL] 39.8 ± 7.5 52.7 ± 14.2 48.9 ± 18.4 0.07
LDL cholesterol [mg/dL] 97.3 ± 25.3 122.8 ± 40.2 115.2 ± 33.4 0.34
Triglycerides [mg/dL] 137.0 ± 11.0 152.0 ± 61.8 174.9 ± 95.2 0.40
Treatment:
Acetylsalicylic acid 8 (100%) 28 (78%) 93 (80%) 0.14
Clopidogrel 2 (25%) 5 (14%) 25 (22%) 0.44
Statins 8 (100%) 35 (97%) 103 (89%) 0.63
Fibrates 2 (25%) 4 (11%) 28 (24%) 0.30
ACEI 4 (50%) 30 (83%) 94 (81%) < 0.05
ARB 4 (50%) 6 (17%) 23 (20%) < 0.05
Beta-adrenolytics 8 (100%) 33 (92%) 103 (89%) 0.40
Diuretics 4 (50%) 19 (53%) 62 (53%) 0.89
CCA 3 (38%) 9 (25%) 39 (34%) 0.47
Metformin 6 (75%) 27 (75%) 69 (59%) 1.00
Sulfonylurea derivatives 3 (38%) 11 (31%) 58 (50%) 0.70
Insulin 2 (25%) 15 (42%) 37 (32%) 0.38
Previous incidents:
Previous acute coronary syndrome 3 (38%) 15 (42%) 50 (43%) 0.83
Previous stroke 1 (13%) 8 (22%) 19 (16%) 0.54
Data are presented as mean values ± SD or numbers (percentages). ACEI — angiotensin-converting enzyme inhibitors; ARB — angiotensin II re-
ceptor blockers; BMI — body mass index; CAD — coronary artery disease; CCA — calcium channel antagonists; HbA1c — glycated hemoglobin; 
HDL — high-density lipoprotein; LDL — low-density lipoprotein
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they were analyzed manually. Secondly, we were not 
able to use the same electrocardiographic devices for 
all patients in different regions of Poland. Thirdly, some 
subgroup analyses in our study were underpowered. 
Fourthly, we did not assess left ventricular mass or 
wall thickness by echocardiography or magnetic res-
onance imaging and therefore we could not calculate 
the specificity or sensitivity of the compared ECG-LVH 
criteria. Finally, further studies are needed to verify the 
prognostic values of various ECG-LVH criteria.
Conclusions
The co-occurrence of all assessed ECG-LVH criteria, 
including the three most frequently applied in clinical 
practice, is very low in diabetic CAD patients. The Romhilt- 
-Estes point score identifies the highest number of 
ECG-LVH cases in this setting. However, it seems reason-
able to use routinely several ECG criteria for detection of 
LVH. Further studies are needed to compare diagnostic 
values of ECG-LVH criteria with imaging methods and to 
assess prognostic values of various ECG-LVH criteria.
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